Literature DB >> 6102459

Blood monoamine metabolism in Huntington's disease.

K Belendiuk, G W Belendiuk, D X Freedman.   

Abstract

In 25 patients with Huntington's disease (HD), the mean blood concentration of serotonin (5-HT) and percentage of plasma free tryptophan were significantly increased while plasma concentrations of total and protein-bound tryptophan were significantly decreased. The pattern of changes in tryptophan concentrations was related to clinical severity but not to 5-HT levels. Platelet monoamine oxidase (MAO) activity was significantly increased in patients with HD; kinetic and marker enzyme studies suggested an increased enzyme concentration. Offspring at risk for HD also had elevated platelet MAO activity but normal concentrations of blood 5-HT and plasma tryptophan. In ten patients, plasma epinephrine concentrations were significantly increased; plasma dopamine and norepinephrine concentrations were positively related to MAO activity. The finding of peripheral neurotransmitter abnormalities in HD raises the question of an interaction between CNS and peripheral processes or a systemic disorder of neurotransmitter metabolism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6102459     DOI: 10.1001/archpsyc.1980.01780160095011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  10 in total

Review 1.  The current state of research with peripheral tissues in Huntington disease.

Authors:  G C Beverstock
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

2.  Serotonin and measured intelligence.

Authors:  E H Cook; B L Leventhal; D X Freedman
Journal:  J Autism Dev Disord       Date:  1988-12

3.  Abnormal platelet aggregation response in Huntington's disease.

Authors:  Y Muramatsu; H Kaiya; H Imai; M Nozaki; H Fujimura; M Namba
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

4.  Results of the citalopram to enhance cognition in Huntington disease trial.

Authors:  Leigh J Beglinger; William H Adams; Douglas Langbehn; Jess G Fiedorowicz; Ricardo Jorge; Kevin Biglan; John Caviness; Blair Olson; Robert G Robinson; Karl Kieburtz; Jane S Paulsen
Journal:  Mov Disord       Date:  2013-12-27       Impact factor: 10.338

5.  Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls.

Authors:  J J Mann; R D Kaplan; E D Bird
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

6.  Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.

Authors:  Jolene Ooi; Michael R Hayden; Mahmoud A Pouladi
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

7.  A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.

Authors:  Xin Du; Terence Y C Pang; Anthony J Hannan
Journal:  Front Neurol       Date:  2013-07-09       Impact factor: 4.003

8.  Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.

Authors:  Mobina Fathi; Kimia Vakili; Shirin Yaghoobpoor; Arian Tavasol; Kimia Jazi; Ramtin Hajibeygi; Sina Shool; Fatemeh Sodeifian; Andis Klegeris; Alyssa McElhinney; Mostafa Rezaei Tavirani; Fatemeh Sayehmiri
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

Review 9.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018

10.  Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy.

Authors:  Kok Pin Ng; Joseph Therriault; Min Su Kang; Hanne Struyfs; Tharick A Pascoal; Sulantha Mathotaarachchi; Monica Shin; Andrea L Benedet; Gassan Massarweh; Jean-Paul Soucy; Pedro Rosa-Neto; Serge Gauthier
Journal:  Neuroimage Clin       Date:  2019-11-13       Impact factor: 4.881

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.